New quarterly report expected Apr 23, 2026. Report will refresh after results.
C
Chemed Corporation
CHE · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 15, 2026
Demographic Inevitability Hostage to a Single Government Payer
The market is treating 2025's earnings miss as a valuation reset event, but the deeper question it hasn't priced correctly is whether three simultaneous operational failures — Medicare CAP mismanagement, Google SEO collapse, and insurance AI write-offs — represent coincidental cyclical noise or the first signal that both businesses face structural headwinds in their most profitable revenue streams. If management is right that these are fixable, the current multiple is a gift; if even one is structural, the five-year earnings trajectory looks very different from the demographic story the bulls are telling.
Flowly Score
Apr 16 Close
+33%$382.88
Fair Value
$510.00
61
Averageat $382.88
Business Strength7/10
VITAS's referral network depth, CON barriers, and process complexity create a genuine moat that PE-backed entrants can't simply buy — but a single government payer setting your price is a structural ceiling no competitor could impose. Roto-Rooter is a steady-state brand advantage, not a compounding flywheel, and the governance texture (nepotism flag layered onto prior DOJ settlement) prevents a clean score.
Financial Resilience7/10
Cash consistently outpaces reported earnings, capital intensity is minimal, and the Altman Z suggests no near-term distress — this business does not need external capital to survive or grow. The sharp cash drawdown and aggressive leveraged buybacks in a year of margin compression is a capital allocation posture worth watching, not yet alarming.
Growth & Trajectory5/10
The demographic tailwind is as close to calendared demand as any business gets, and 2026 guidance suggests 2025 was a trough — but the combination of Google SEO collapse, insurance AI-driven write-off inflation at Roto-Rooter, and a deliberate VITAS mix shift that sacrificed margin for cap compliance makes the trajectory genuinely murky in the near term. Revenue growing while earnings collapsed is operating deleverage in the wrong direction.
Valuation7/10at $401.87
The multiple has compressed dramatically from its five-year range to a level that prices in substantial ongoing impairment — which appears to be overcorrection given that 2025's issues are predominantly self-described and partially self-inflicted. The pessimistic DCF scenario is barely negative, which means the downside is bounded and the upside in a normalization scenario is meaningful.
Risk4/10
Three specific, named risks have materialized simultaneously — Medicare CAP exposure that forced a damaging mix shift, Google's algorithmic shift gutting organic leads, and insurance company AI scrutinizing Roto-Rooter billings — and none of them are fully resolved. The existential concentration in a single government payer that sets price unilaterally, compounded by prior compliance failures, means the tail risk is genuinely fat.
Chemed sits at the intersection of genuine quality and legitimate concern — and right now, the price reflects the concern more than the quality. The FCF yield, the multiple compression relative to five-year averages, and the bounded pessimistic DCF scenario all point to a business whose stock has been marked down more than its moat warrants. VITAS is the largest hospice provider in the country executing against the most predictable demand curve in healthcare — aging Americans, underpenetrated utilization, and four new CON territories awarded in two years. That combination doesn't get cheaper often. The 2026 path is a deliberate rebalancing act: VITAS exits its cap-avoidance mix shift and reloads toward longer-stay patients who generate the unit economics the business was built on, while Roto-Rooter centralizes billing and recovers write-offs that management quantified and expects to recapture. These are operational fixes, not structural reinventions — and management's unusual candor about the EPS miss ('it's big and it's causing a lot of change') suggests they understand the stakes. The second-half weighting of 2026 earnings is a signal: the fixes take time, but they're in motion. The single biggest risk is not competition, not housing cycles, not even governance — it is the Medicare hospice reimbursement framework itself. CMS has the unilateral authority to tighten CAP calculations, reduce per-diem rates, or narrow eligibility definitions in a single rulemaking cycle. VITAS demonstrated in 2025 exactly how damaging CAP exposure can be when it forced a strategic admissions shift that cost margin, census mix, and earnings in a single year — and that was a self-managed response to a known liability. A regulatory change that arrives without warning, at a business where pricing is set by the regulator and costs are set by the labor market, is the scenario where the demographic tailwind becomes irrelevant.